Guillain-Barré syndrome (GBS) is a severe acute paralytic neuropathy, often triggered by infections. Although rare, vaccines have also been associated with GBS. We report a case of GBS following the second dose of the BNT162b2 (Pfizer®) COVID-19 vaccine in a 25-year-old woman with no prior comorbidities. She developed progressive lower limb weakness and paresthesias four days before admission. Clinical, electrophysiological, and laboratory findings confirmed the diagnosis of GBS, with no other evident triggering factors. The patient was treated with intravenous immunoglobulin (IVIg) and showed significant improvement within 30 days. This case adds to the limited reports of GBS following COVID-19 vaccination. While causality remains uncertain, further surveillance and investigation are necessary to understand the potential link between COVID-19 vaccines and immune-mediated neuropathies.
Guillain-Barré syndrome following BNT162b2 COVID-19 vaccine
Trimboli M.;Zoleo P.;Arabia G.;Gambardella A.
2021-01-01
Abstract
Guillain-Barré syndrome (GBS) is a severe acute paralytic neuropathy, often triggered by infections. Although rare, vaccines have also been associated with GBS. We report a case of GBS following the second dose of the BNT162b2 (Pfizer®) COVID-19 vaccine in a 25-year-old woman with no prior comorbidities. She developed progressive lower limb weakness and paresthesias four days before admission. Clinical, electrophysiological, and laboratory findings confirmed the diagnosis of GBS, with no other evident triggering factors. The patient was treated with intravenous immunoglobulin (IVIg) and showed significant improvement within 30 days. This case adds to the limited reports of GBS following COVID-19 vaccination. While causality remains uncertain, further surveillance and investigation are necessary to understand the potential link between COVID-19 vaccines and immune-mediated neuropathies.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
